Proteins are the effector molecules of many cellular and biological processes and are thus very dynamic and flexible. Regulation of protein activity, structure, stability, and turnover is in part controlled by their post-translational modifications (PTMs). Common PTMs of proteins include phosphorylation, glycosylation, methylation, ubiquitination, acetylation, and oxidation. Understanding the biology of protein PTMs can help elucidate the mechanisms of many pathological conditions and provide opportunities for prevention, diagnostics, and treatment of these disorders. Prior to the era of proteomics, it was standard to use chemistry methods for the identification of protein modifications. With advancements in proteomic technologies, mass spectrometry has become the method of choice for the analysis of protein PTMs. In this brief review, we will highlight the biochemistry of PTMs with an emphasis on mass spectrometry.
Introduction

Chemistry of Proteins
Proteins are biopolymers that are made up of amino acids and can therefore be viewed as chemical molecules. Posttranslational modifications (PTMs) of proteins make use of the many functional groups present on a protein backbone with different side chains. We can distinguish between two types of PTMs. One occurs by the enzyme-catalysed covalent addition of an electrophilic group to the mostly nucleophile side chain residues of the protein. The other type occurs through covalent cleavage of peptide backbones. Of the 22 proteinogenic amino acids known, only leucine, isoleucine, valine, alanine, and phenylalanine have not been shown to be modifiable in vivo. [1] The amino acid residues of proteins are mostly nucleophilic with the cysteinic thiol group being one of the most used for the regioselective modification of proteins. Thiol groups of cysteines can undergo numerous reactions such as alkylation (with a-haloketones or Michael acceptors, e.g. maleimide derivatives). Another functional nucleophilic group used in amino acid residues is the e-amino group of lysine. There are many reactions based on the site-specific modification of primary amines in proteins. Reactions of lysines with esters (formation of amides), sulfonyl chlorides (building of sulfonamides), isocyanates (production of ureas), and isothiocyanates (thioureas) are common. [2] Furthermore, the functional side chains of arginine, histidine, aspartic acid, glutamic acid, and tyrosine can acts as nucleophiles as well. In general, the nucleophilicity order of amino acids follows the trend: R-S À . R-NH 2 .. R-
However, this order depends on several other factors such as the polarisability of the nucleophile or the solvent used (protic or aprotic) or the conjugation of the nucleophile. For example, R-COO À (carboxylate) is less nucleophilic than R-O À (alkoxide) because of conjugation. Through chemistry, non-proteinogenic amino acids and other functional groups can be introduced into proteins.
PTM Proteomics: Biological Implications
The human genome encodes ,25000 genes, of which ,2 % code for protein synthesis. However, due to alternative splicing mechanisms, ,100000 proteins are genetically encoded. Furthermore, by means of PTM Proteomics: Biological Implications, this number increases to some 1-2 million protein entities. [3] PTMs can occur either enzymatically (phosphorylation, glycosylation) or non-enzymatically (glycation, oxidation) ( Fig. 1) . [4] Protein PTMs expand the dimension and the repertoire of functions performed by these biomolecules. [5] Hundreds of unrelated PTMs exist that are known and characterised with regard to their involvement in physiological and pathological bioprocesses (Fig. 1 ). For this reason, it is of high importance to identify and characterise PTMs to be able to prevent and treat diseases. Most PTMs are reversible, but can also be spontaneous (no involvement of enzymes).
Proteomics is designed to identify proteins, their sequence, and known modifications as well as their quantitation in a biological sample. [6] [7] [8] [9] [10] [11] [12] [13] [14] It is likely that due to challenges associated with analytical techniques and data analysis, many protein modifications are still to be determined.
Every proteomics experiment starts with a biomaterial. Biomaterials commonly used and cited in the literature include immortalised cancer cell lines (marked by unlimited proliferation) and whole organisms (e.g. yeast, bacteria). The analysis of tissue samples or primary cells (cells freshly gained from a tissue sample) is only seldom performed due to their very low protein content. [15] [16] [17] [18] [19] However, immortalised cancer cell lines have undergone mutational changes in regulatory proteins of the cell cycle, cell-cell communication, and apoptosis in contrast to primary cells which still represent a genuine physiological state in vivo. [20] [21] [22] Frequently, the results of PTMs proteomics studies require extensive investigation to elucidate the significance of the data. [8, [23] [24] [25] [26] [27] [28] [29] [30] Identification, localisation, and quantification of modifications still do not reveal the effectors of change, the pathways in which this occurs, or the functional impact of
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Identification by mass spectrometry the modification on the protein. All these questions can be answered only by using biological tools such as cell culture experiments or knockout models. [31] PTMs are more predominant in eukaryotes than prokaryotes, with ,5 % of the genome of eukaryotes coding for enzymes involved in protein modifications.
Mass Spectrometry of Proteins
Mass spectrometry (MS) has been established as an indispensable tool for the characterisation of proteins and protein complexes. In general, a mass spectrometer is made of three main parts: an ion source in which peptides or biomolecules are positively or negatively ionised, an analyser in which the separation of gas phase ions occurs according to their mass-tocharge (m/z) ratio, and finally a detector that generates the signal in the form of a spectrum. There are different proteomic approaches to analyse biomolecules. In bottom-up proteomics, proteins are digested into short peptides before MS. [29, [32] [33] [34] When intact whole proteins or biomolecules are directly investigated by MS, this is referred to as a top-down approach. [35] Recently, a middle-down approach has been introduced as the variant in which fragmentation is performed on large polypeptides (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . [36] The choice of a specific approach depends on the analysis to be performed and on the instrumentation available. A top-down approach heavily depends on instrumentation as it requires higher mass accuracy compared with other techniques. For a top-down approach, usually a Fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometer is the instrument of choice whereas a bottomup approach works well with ion-trap-based instruments with high speed tandem MS (MS/MS) scanning. With regard to applications, top-down is mainly recommended for combinatorial PTMs analysis and bottom-up for shotgun sequencingbased identification of low stoichiometric modification sites. [37] Shotgun MS refers to a data-dependent acquisition (DDA) mode in which peptide ions are selected for fragmentation based on their intensity. In contrast to DDA, targeted methods (such as selected reaction monitoring) identify so-called transitions in a data-independent acquisition mode. [38] Targeted approaches are superior to shotgun methods with regard to their detection limit and dynamic range. Also, various instruments use different fragmentation methods: collision-induced dissociation (CID), electron transfer dissociation (ETD), [39] and electron capture dissociation (ECD). [40] In CID, accelerated gas phase peptidic ions collide with an inert gas (e.g. argon or helium), and this results in partial conversion of the kinetic energy into internal energy and thus fragmentation. Ion trap instruments are run under low-energy CID whereas beam-type CID is performed in triple quadrupoles (QqQ) and quadrupole time-of-flight (Q-TOF) instruments. [41] In ETD, anions with low-electron affinities transfer electrons to the cationic peptide resulting in the release of a hydrogen radical to the backbone carbonyl group. [39] With ETD, fragmentation of the radical peptide ions results in c-and z-ions contrary to the b-and y-series obtained with CID fragmentations. ECD has the same fragmentation pattern as ETD, but is only performed on FT-ICR mass spectrometers, which is among the most expensive MS instruments. Furthermore, ETD is also preferred when it comes to the identification of multiple PTMs.
In the case of ETD and ECD, labile PTMs modifications such as phosphorylation or N-and O-glycosylation remain intact, allowing direct identification of the site of modification. [40] Given that in ETD, peptides fragment most efficiently when they are triply charged (3þ) ions rather than doubly charged (2þ) ions as CID, and knowing that (2þ) ions correspond to the largest proportion of charged tryptic peptides, CID is thought to have a slight advantage before ETD, mostly in large-scale proteomics. In addition, the ETD reaction is much slower than CID. [42] Whatever approach is used, protein identification is performed by matching the fragment ion spectrum against a database containing deposited MS/MS spectra of in silico protein digests. [43] PTMs Proteins can be reversibly chemically altered after being synthesised by translation machinery. These PTMs are mostly by chemical functional groups (phosphate, carbohydrate, methyl, ubiquitin) that are covalently attached to amino acids. PTMs affect protein activity, turnover, and protein-protein interactions (PPI). Common PTMs include phosphorylation, ubiquitination, methylation, glycosylation, acetylation, oxidation, and many more. These modifications are carried out by a diverse group of enzymatic units including kinases, ubiquitin ligases, and acetyl-transferases and are tightly regulated and conserved across species. The observation that diseases such as cancer are characterised by a high rate of mutations of PTMs effectors (kinases, ubiquitin E3 ligases) reveals the important role PTMs play in many cellular processes. [44] Therefore, their identification and characterisation is of primary importance. Another interesting observation is the fact that most of the PTMsmediating enzymes are themselves regulated by other PTMs resulting in complex PTMs networks. [45, 46] So far, ,200 or more different PTMs have been detected in the human proteome. It is now well known that an amino acid harbours several distinct modifications, such as the case with the amino acid lysine which can be methylated, acetylated, or ubiquitinated. [47] For instance, phosphorylation (mostly on serine, threonine, and tyrosine) and ubiquitination (on lysine residues) have been shown to interact in epidermal growth factor stimulation experiments. [15, [48] [49] [50] PTMs were originally identified by chemical methods such as Edman degradation, amino acid analysis, and radioisotope labelling. However, these methods present some limitations: low throughput, low specificity, and a narrow dynamic range. Furthermore, modification sites are difficult to predict using chemical methods. In the past decade or so, MS has become the method of choice for the analysis of protein PTMs with regards to their identification or discovery, their quantification, as well as their cross-talk. [43, 51] Generally, MS identification of PTMs involves several steps. The first step is usually an enrichment step due to the transient, labile, and low-stoichiometry (lower fmol range) of most PTMs. Several enrichment methods exist. Chemical derivatisation is a general technique used for enrichment of modified phosphopeptides and O-glycosylated residues. Usually, the phosphate group or sugar residues undergo a b-elimination followed by Michael addition. The disadvantages of this method are multiple. First, not all protein modifications undergo b-elimination. Second, the reaction is not very efficient. Finally, chemical byproducts from backbone cleavages occur frequently. [52] [53] [54] [55] Other enrichment methods make use of antibodies specific for the modified residues for selective enrichment of the PTMs (e.g. antiphosphotyrosine antibodies). Depending on the efficiency of the analytical technique employed, this step can also be performed at the peptide level. The next step is then the proteolytic digestion of the enriched proteins and MS analysis of the modified peptides. These peptides have a characteristic fragmentation pattern, resulting in a specific signature of the modified peptides. This signature is mostly a mass shift. Once the precursor ion that corresponds to modified peptide is detected in MS mode, the MS/MS fragmentation would allow sequencing of the modified peptides for the identification and localisation of mass shifts. In addition, diagnostic ions or chemical processes predicted to happen (e.g. neutral loss of a phosphate group) may also be good indicators of the type of modification and its location. In some cases, however, the mass shifts might be ambiguous to assign. An example is the mass shift of a tri-methylation (42.047 Da) and an acetylation (42.010 Da), which are very close and would require highly sensitive and accurate MS instrumentation (FT-ICR or LTQ ion trap orbitrap) to distinguish. Otherwise one would have to look for diagnostic ions and neutral loss in MS/MS spectra. [56] During fragmentation (CID, ECD, and ETD), low mass ion signals from neutral losses and other peptide backbone fragments are observable and can be utilised in the identification and localisation of modification sites. After the analysis of samples, peptide sequences and sites of modifications can be assigned using an appropriate search engine. Finally, results should be reproduced and validated to exclude false-positive identifications or artefacts ( Fig. 1 ). An overview of basic information on all the PTMs discussed in this review is shown in Table 1 .
Phosphorylation
Phosphorylation of proteins is one of the most studied reversible protein modifications. It occurs through the covalent attachment of a phosphoryl group to a serine, threonine, or tyrosine. This modification is known to affect regulation of protein synthesis, activity and stability, inter-/intracellular signalling, gene expression, cell survival, and apoptosis. [49, 57] Therefore, deregulation of phosphorylation events can lead to many diseases such as cancer. Consequently, identification and characterisation of phosphoproteins would be useful in unravelling the pathomechanisms involved in the above-mentioned diseases. Protein phosphorylation and dephosphorylation are carried out by kinases and phosphatases, respectively. Kinases catalyse the transfer of a phosphoryl group from adenosine triphosphate or guanosine triphosphate to serine, threonine, or tyrosine through formation of a phosphoester bond. This bond can in reverse be hydrolysed by phosphatases, releasing orthophosphate. [58, 59] Due to the demonstrated faster kinetics of phosphatases compared with kinases, phosphatases have to be inactivated during phosphoproteomics experiments. [60] So far, more than 500 kinase-coding human genes and ,150 phosphatases are known, demonstrating the importance of this modification in cellular and biological events. [61] [62] [63] Phosphoserines are the most abundant phosphogroups (,86.4 %) present in the human proteome followed by phosphothreonines (11.8 %) and phosphotyrosines (1.8 %). [15] However, phosphorylations of histidine, aspartate, and arginine have also been demonstrated, mainly in bacteria. [64, 65] MS based phosphoproteomics determines phosphorylated proteins and phosphorylation sites in distinct cells, tissues, or organisms. [45, 57] Generally, phosphopeptides are first generated by proteolytic digestion for the analysis of phosphopeptides. During fragmentation of the phosphopeptides, the phosphoryl group of phosphoserine and phosphothreonine is b-eliminated as phosphoric 114.043 -acid to give dehydroalanine (DHA) and dehydro-2-aminobutiric acid (DHAB), respectively. The 98 Da neutral loss of phosphoric acid as well as the formation of DHA and DHAB are indicative of the location of serine or threonine phosphorylation. [66] Unlike threonine or serine, tyrosine has a neutral loss of HPO 3 (80 Da) . For enrichment of phosphopeptides, the two most employed techniques are TiO 2 affinity chromatography and immobilised metal affinity chromatography (IMAC). In some cases, fractionation of the samples by other chromatographic means (size exclusion chromatography or ion exchange chromatography) precedes enrichment in order to reduce sample complexity. Combinations of two or more purification methods for phosphopeptides, such as TiO 2 affinity chromatography and IMAC, to give TIMAC, are also common. Current reports of identifications of 10000-20000 phosphorylation sites in large-scale proteomics experiments are frequent, although it is believed that many more sites are missed in these analyses. [16, 67, 68] Ubiquitination Ubiquitination is one of the well studied main regulatory modifications that occur through covalent attachment of the C-terminus of ubiquitin, a 76-residue polypeptide highly conserved among eukaryotes, by an isopeptide bond to the e-amino group of lysine residues of another protein. Ubiquitination is relevant for protein homeostasis, cell cycle progression, gene transcription, receptor transport, and immune responses. [69] The process is directed by the action of three enzymes: ubiquitinactivating enzyme E1, ubiquitin-conjugating enzyme E2, and ubiquitin-ligating enzyme E3. E1 activates ubiquitin in an adenosine triphosphate-dependent manner leading to the transfer of ubiquitin to the active cysteine site of E1 through a thioester bond and release of adenosine monophosphate. Subsequently, ubiquitin is conjugated to the active cysteine site of E2 thus allowing E3 to attach it to a lysine residue on a particular protein through a thio-esterification reaction. [70] Ubiquitination can also be reversed by the action of de-ubiquitinating enzymes (DUB). [71, 72] Due to its comparable size (,700 E1, E2, E3, and DUB) to the phosphorylation system (650 kinases and phosphatases [73] [74] [75] ), ubiquitination is considered a proteome-wide modification. Ubiquitination does not target lysine residues based on sequence recognition motifs, but rather on the accessibility of the lysine residues or the specificity of the E3 enzyme or E2/E3 enzymes. [46, [76] [77] [78] [79] The detection of ubiquitinated peptides occurs by proteolytic digestion of samples that yield a characteristic di-glycine (diGly) signature resulting from the strong attachment of the two C-terminal glycine residues of ubiquitin to the lysine residue. Therefore, ubiquitinated peptides have an additional mass of 114.043 Da compared with unmodified peptides making it also possible to predict ubiquitination sites. This approach was successfully used in large-scale ubiquitination sites mapping of the yeast proteome. [80] Recently, monoclonal antibodies specific against di-Gly-peptides have been reported in the literature as an enrichment tool at the peptide level. Using these antibodies, a few studies reported the identification of 11000 and 19000 sites of ubiquitination, respectively. [81, 82] Methylation Proteins can be methylated mostly on their lysine and arginine residues, although methylation of histidine, cysteine, aspartic acid, glutamic acid, serine, and threonine has also been observed. Methylation of proteins affects biological processes such as transcriptional regulation, RNA processing, metabolism, and signal transduction. [83] [84] [85] For the methylation of lysine, one to three methyl groups from S-adenosyl-methionine (SAM) are transferred to the lysine e-amine side chain, whereas arginine can be singly-or doubly-methylated by adding the methyl group to its guanidine group. Enzymes that recognise a specific protein sequence or motifs for methylation are called methyltransferases. These enzymes require SAM as a co-factor in DNA and protein methylation as well as for epinephrine and phosphatidylcholine synthesis. [86] Prior to MS analysis of methylated peptides, an enrichment step is generally undertaken. Mostly, methyl lysine-or methyl arginine-specific antibodies are used for enrichment. [87] Fragmentation of methylated peptides whether by CID or ETD generates ion signals in the low mass range originating from neutral losses and other peptide backbone fragments as well as a mass shift of 14.0156 in the mono-methylated peptide compared with the non-modified variant. In the case of CID, these losses can be water losses or methylamine, methylguanidine, or methylcarbodiimide whereas ETD produces mostly methylarginine-related neutral losses. [88] [89] [90] [91] Finally, methylation has been shown to be interrelated to other PTMs such as acetylation, phosphorylation, and ubiquitination. For instance, the half-life of a protein can be extended by preventing ubiquitination of this protein by means of lysine methylation. [92, 93] Glycosylation Glycosylation is the most common form of PTMs found with a prevalence of ,50 % in the human proteome. [94] Glycosylation can be of either two types: N-linked at a consensus sequence of Asn-Xaa-Ser/Asn-Xaa-Thr (NXS/NXT; Xaa is any amino acid except proline) by the nitrogen of side chains of extracellular proteins or O-linked by the hydroxy oxygen of serine, threonine, tyrosine, hydroxylysine, or hydroxyproline side chains of both extracellular, nuclear, and cytoplasmic proteins. [95] [96] [97] [98] [99] Glycosylation is an extremely complex and heterogeneous modification as glycoproteins harbour a mixture of glycoforms. The process of glycosylation follows two main steps. In the first step, protein motifs are recognised by glycosyltransferases which then transfer the first monosaccharide (or preformed oligosaccharide for N-glycosylation) onto the recognition site. In the second step, other glycosyltransferases (and glycosidases for N-glycosylation) work sequentially to generate distinct glycan structures. Glycosylation of proteins enable them to accomplish many cellular functions such as proper folding of proteins, stabilisation of proteins, cell-cell adhesion, and communication. [100] Glycosylation has also been linked to many pathological states (cancer, infectious diseases) and could be used as a marker in diagnostics. [101] Already, numerous drugs on the markets are glycoproteins that have well characterised glycan entities necessary for their function, efficacy, and safety. [102] The aim of any proteomic investigation of glycosylation by MS is to characterise the glycan structure attached to the protein with regard to site of localisation, glycan structure, and quantification. Due to the highly complex and heterogeneous nature of glycosylation, several strategies are available for glycoproteomics. Generally, glycans are enzymatically (e.g. PNGase F for N-glycans) or chemically (reductive elimination for O-glycans) cleaved from the protein and derivatised (reductive amination) after purification before the MS run. [103, 104] Another strategy consists of undertaking a proteolytic digest of the protein (e.g. with trypsin or pronase) and collecting information on the sequence and site of modification of peptides generated with appropriate MS instrumentation. [105] [106] [107] Depending on the desired major information, many other tailored strategies of glycoproteomics can be adopted. [108, 109] Contrary to glycosylation, glycation refers to the non-enzymatic addition of sugar aldehyde or ketone to the e-amino group of lysines or the N-terminal amino group of proteins. The glycan reaction, also known as the Maillard reaction, leads to the irreversible formation of advanced glycation end products, which can cross-link proteins thus rendering them detergent-insoluble and proteaseresistant. [110, 111] Of the two forms of glycosylation (N-and O-Glycosylation), N-glycosylation is the most common. N-glycosylation occurs in the lumen of the endoplasmic reticulum and is catalysed by the enzyme oligosaccharyltransferase, which transfers saccharides onto the b-amino groups of asparagine in an NXS/T consensus sequon. [112] We have two examples for MS based identification of glycosylation sites: 1) we investigated whether an NXS/NXT N-glycosylation site is occupied by an N-linked oligosaccharide or not and 2) we investigated whether removal of a glycosyl group will indeed convert asparagine from the NXS/NXT glycosylation site into an aspartate.
In the first example, we analysed a peptide mixture that resulted from a trypsin-AspN double digestion; the original protein (IgG heavy chain) was treated with PNGase F prior to a trypsin-AspN double digestion. PNGase F specifically removes the N-linked glycosyl groups from the NXS/NXT glycosylation sites. Here, we identified a doubly-charged peak with m/z of 595.20 that corresponded to a peptide with the sequence EEQYNSTYR. Its MS/MS fragmentation confirmed the amino acid sequence of this peptide. If the peptide EEQYN-STYR was glycosylated, the PNGase F treatment would have converted the asparagine from the NST site into aspartate resulting in a net gain of 1 Da and thus creating a cleavage site for AspN (aspartate, but not asparagine, is a substrate for AspN). Conversely, if the MS/MS fragmentation determines that the peptide EEQYNSTYR has an asparagine at the NST site, then the NST site is not occupied by any oligosaccharides. At the same time, identification of the asparagine at the NST site would also exclude the deamidation of the asparagines as a possible scenario, which easily mimics the PNGase F treatment in an MS/ MS experiment (deamidation of asparagine and its conversion into aspartate). The total ion chromatogram, the extracted ion chromatogram for the precursor ion with the m/z of 595.20, the mass spectrum (TOF MS) showing the doubly-charged precursor ion, as well as the MS/MS of the precursor ion that led to identification of the peptide with the sequence EEQYNSTYR is shown in Fig. 2 .
In the second example, proteins were subjected to a PNGase F treatment and then to trypsin-AspN double digestion and the resulting peptide mixture was analysed by liquid chromatography (LC)-MS/MS. We identified in MS mode a precursor peak with m/z of 482.53 (3þ) that corresponds to a peptide with the amino acid sequence DSSSSQFQIHGPR. Within the protein sequence, the original sequence of the peptide was NSSSSQFQIHGPR. Therefore, since the peptide could not have been produced by trypsin, AspN, or trypsin-AspN double digestion and asparagine deamidation can be eliminated as a possible explanation of asparagine conversion into aspartate in the peptide DSSSSQFQIHGPR (asparagine deamidation happens almost exclusively within the MS experiment, after the proteins are digested), this suggest that MS and MS/MS identification of the DSSSSQFQIHGPR-peptide indicates that the original peptide within the protein is NSSSSQFQIHGPR, with asparagine occupied by an oligosaccharide. The total ion chromatogram, extracted ion chromatogram, mass spectrum, and MS/MS mass spectrum that led to the identification of the peptide with the amino acid sequence DSSSSQFQIHGPR are shown in Fig. 3 .
Acetylation
Acetylation was first discovered on histones and later was also found on more than 80 transcription factors and other nuclear regulatory biomolecules. Protein acetylation has been shown to be involved in many different cellular processes including transcription and metabolic regulation. It has been shown that most enzymes involved in glycolysis, gluconeogenesis, the tricarboxylic acid cycle, the urea cycle, fatty acid metabolism, and glycogen metabolism are acetylated. [113] [114] [115] [116] [117] Histone acetylation influences gene transcription as the non-acetylated forms of histones repress transcription compared with acetylated histones. Histone acetyltransferases (HAT) are the enzymes that transfer the acetyl group from acetyl-coenzyme A to the amino group of lysine at the N-terminus of histones to form 3-N-acetyl lysine whereas histone deacetylases (HDAC) reverse this process. [114] Therefore, since uncontrolled protein acetylation can lead to pathological conditions such as obesity, cancer, and neurodegenerative diseases, [117] HAT and HDAC are being pursued as drug targets for the above cited disorders. [118] [119] [120] [121] For the investigation of acetylation by MS, the strategy adopted is almost the same as for the previous mentioned PTMs. First, proteins are digested with trypsin into peptides, which can then be analysed by LC-MS/MS. Acetylation is not lost during sequencing of the peptide by CID and results in a mass shift of 42.01 Da to the unmodified peptide. [122] Unfortunately, this mass shift corresponds to another PTMs, specifically trimethylated lysine (42.04 Da), so that precaution should be taken when assigning acetylation based on mass shift. Through neutralisation of the charge on lysine, acetylation can also prevent trypsin cleavage and this can be used as evidence of lysine modification. As for enrichment methods, immunoaffinity purification using antibodies against acetyl-lysine is the standard method. Using immunoaffinity purification and isoelectric focussing, a group reported the discovery of more than 3600 acetylated sites on 1750 proteins from a human leukemia cell line. [113, 121] Acetylation is catalysed endogenously by a set of acetyltransferases, but can also be carried out in vitro on chemically synthesised peptides which often have free amino and carboxy termini and are thus charged. Generally, this charge can be eliminated by N-terminal acetylation and/or C-terminal amidation of the peptide that then mimics natural peptides (e.g. increased cell permeability or activity) and is more stable. Moreover, these terminal modifications (acetylation and amidation) prevent additional modifications of the peptide N-and C-termini. Therefore, acetylation is wanted specifically at the N-terminus whereas amidation is selectively preferred C-terminally. Peptide synthesis was performed by Fmoc solidphase synthesis. Glutamine residues are acetylated at the end of peptide synthesis by deprotection of the Fmoc-group and reaction of the N-terminal glutamine with dimethyl formamide, acetic anhydride, and N,N-diisopropylethylamine. Fig. 4 shows an example where a synthetic peptide was analysed by direct infusion electrospray ionisation (ESI)-MS and ESI-MS/MS and then investigated for identification of the acetylated peptide and for localisation of the site of acetylation. The peptide investigated had the amino acid sequence QLQLQLQLQLQLKK, it was amidated at the C-terminus and it was acetylated, either at the N-terminus or at one of the two lysine residues. The predicted m/z of the singly charged (1þ) unacetylated, amidated peptide was 1721.08, while the predicted m/z of the (1þ) acetylated and amidated peptide was at the N-terminal glutamine residue produced a good match between the theoretical and experimentally detected b and y ions, suggesting that the peptide is acetylated at the N-terminal glutamine residue. Additional evidence that the peptide was acetylated at the N-terminal glutamine residue and not at another residue came from the inspection of the experimentally detected b and y ions. In our experiments, we identified the unmodified y8-y11 ions, which correspond to LQLQLQLQLKK (y11), QLQLQLQLKK (y10), LQLQLQLKK (y9), and QLQLQLKK (y8), suggesting that 1) the c-terminal part of the peptide is not acetylated, 2) none of the two lysine residues are acetylated, and 3) the N-terminal part of the peptide (specifically one of the first four N-terminal amino acids QLQL) is acetylated. In our experiments, we also identified the b1-b4 and b6 ions, which correspond to Q (b1), QL (b2), QLQ (b3), QLQL (b4), and QLQLQL (b6), all of them acetylated. These results 1) confirm the indication by the y ions that the acetylation is one of the first four N-terminal amino acids and 2) restricts the acetylation to only one amino acid (through detection of b1): the N-terminal glutamine. Oxidation Oxidative PTMs of proteins is a very well described process. This phenomenon can be caused by a multitude of reactive species including reactive oxygen species (superoxide, hydrogen peroxide, hydroxyl radical), reactive nitrogen species (nitric oxide, dinitrogen trioxide, peroxynitrite, nitroxyl anion), and reactive lipid species (lipid aldehydes). [123] [124] [125] The latter species can be generated endogenously or can be acquired through nutrition or the environment. Oxidative modification of proteins can cause DNA base modification, phospholipid damage, and irreversible protein oxidation leading to cell death or mutagenesis. However, depending on several key factors (reactivity and specificity of reactive species, levels of reactive species, location of production, levels of antioxidants and antioxidant enzymes, cell type, and differentiation state), reactive species can contribute to cellular protection, improved metabolism, resistance to oxidative damage, and cellular signalling. [125, 126] The amino acids tyrosine and cysteine constitute the most common protein residues modified by reactive species. For example, it has been suggested that protein nitrotyrosine modifications are associated with the development of several pathologies including heart failure, atherosclerosis, aging, and hypertension. [127] Cysteine, which represents only 1.9 % of protein residues, has been shown to participate in redox signalling and homeostasis. [128] The thiol group of cysteine exists mostly in the deprotonated thiolate anion form due to the low pK a of thiols. This nucleophilic thiolate group can then react with electrophilic reactive species by nucleophilic substitution reactions or by Michael addition to form covalent adducts. [129] [130] [131] [132] Oxidation is very easily identifiable by MS. For instance, methionine oxidation, which together with cysteine are two of the most common amino acid oxidations, will result in a 16 Da high mass peak in a MS spectrum and a neutral loss of 64 Da in a MS/MS spectrum. [133] Methionine oxidation is one of the most frequently occurring protein alteration events in proteomics to the extent that it is considered as a variable modification in mascot searches. The following example shows a double oxidation of a peptide that contains two methionines and the rationale that we used to identify the sites of oxidation (Fig. 5) . In this example, we analysed a peptide mixture that resulted from a trypsin digestion. Here, we identified a peak with m/z of 769.42 (2þ) that corresponds to a peptide with the sequence VKEGMNIVEAMER and that has a modification of 32 Da (Fig. 5A) . A 32 Da modification could correspond, among others, to oxidation of proline to glutamic acid (þ32), oxidation of methionine to sulfone (þ32), oxidation of two methionines to methionine-sulfoxide, and double oxidation of tryptophan (þ32) to N-formylkynurenine. The MS/MS fragmentation of the peak with m/z of 769.42 (2þ) produced some b and y ions that allowed us to confirm the identity of the peptide VKEGMNIVEAMER, with both methionines oxidised to methionine-sulfoxide (Fig. 5B-D) . Evidence that supports our statement came from analysis of both b and y ions, as well as the precursor ions. A common process that follows oxidation of methionine to methionine-sulfoxide (a 16 Da gain) is a neutral loss of methane-sulfenic acid, easily observable as a 64 Da loss. Therefore, we looked for both b and y ions and precursor ions, but also for the neutral loss of y and precursor ions (y-64). Initially, we identified in the MS/MS spectrum the precursor ion with m/z of 769.44 (2þ) and its neutral loss (64 Da) ion with m/z of 737.49 (2þ), which indicated a methionine oxidation and a neutral loss of methane-sulfenic acid. Upon inspection of the MS/MS spectrum, we also identified y11 and y11-64, y10 and y10-64, y8 and y8-64, y7 and y7-64, y12 (2þ) and y12 (2þ)-64, y4 and y4-64 pairs. While identification of y4, 7, and 8 ion pairs suggest oxidation of C-terminal methionine to methionine sulfoxide and neutral loss of methane-sulfenic acid, identification of the oxidation on y3 ion but not on y1 and y2 ions points towards C-terminal methionine as the oxidized amino acid. In addition, identification of y9 and y9-64, y10 and y10-64, y11 and y11-64, and y12 and y12-64 pairs suggest that both the N-terminal and C-terminal methionines are oxidized. Furthermore, identification of the y10, y10-64, and (y10-64)-64 provides additional evidence that both methionines were oxidised to methionine sulfoxide (identified as y10) and then suffered a neutral loss at one (y10-64) or two ((y10-64)-64) methionines. Finally, identification of unmodified b2, b3, and b4, but of oxidised b5 provided direct evidence that the N-terminal methionine is oxidised. Therefore, through analysis of this MS/MS spectrum, we not only identified evidence that the C-terminal, N-terminal, and both methionines are oxidised and further undergo neutral loss of methane-sulfenic acid, but also provided a rationale for identification of every potential modification using the theoretical modifications and the amino acid sequence of the peptide.
Artificial Modifications: Predicted Alkylation of Cysteine and Unpredicted Alkylation of the N-Terminal Amino Acid
For a typical gel-based proteomic experiment, protein bands are excised from the gel and are in-gel digested by proteases (e.g. trypsin, AspN) and the resulting peptide mixture can be further analysed by MS. To increase sequence coverage and assure better identification, disulfide bridges present in proteins are usually reduced (for example with dithiothreitol) and subsequently alkylated with iodoacetamide (IAA) or iodoacetic acid, which results in an attachment of a methyl carboxyamide (carbamidomethyl or CAM) or methyl carboxy (carboxymethyl) to the sulfur atom, respectively. It was long thought that the alkylation reaction is only specific to cysteine residues, but it has been shown that due to the excessive concentrations of the alkylating reagent, it can also take place at other amino acids such as at the N-terminal amino group of most amino acids. [30] Derivatisation of cysteine by IAA leads to an increase in the mass of the peptide of 57 Da, while alkylation by iodoacetic acid leads to a 58 Da shift. Fig. 6 shows an example of a peptide that harbours an expected CAM at the cysteine residue as well as an artificial alkylation at the N-terminal tyrosine. A peak with m/z of 748.35 (2þ) observed in the MS survey spectrum corresponded to a peptide with the sequence YYCFQGNQFLR, with the cysteine modified to CAM-cysteine (Fig. 6A) . MS/MS fragmentation of this precursor ion with m/z of 748.35 (2þ) produced a series of b and y product ions that led to the identification of the peptide with sequence YYCFQGNQFLR, with cysteine modified by CAM (Fig. 6B) . Evidence for this modification came from analysis of both b and y ion series within the MS/MS spectrum (Fig. 6B) . The mass difference between ions b2 (YY, m/z of 327.13) and b3 (YYC, m/z of 487.16) is 160.03, which corresponds to a CAM-cysteine in peptide YYC. The same difference was also observed between y8 (m/z of 1009.55) and y9 (m/z of 1169.55) product ions in the MS/MS spectrum. The y8 ion corresponds to peptide FQGNQFLR, while the y9 ion corresponds to peptide CFQGNQFLR, with cysteine modified to CAM.
Additional alkylation of the peptide with sequence YYCFQGNQFLR, which is already alkylated at the cysteine residue (to CAM) would increase its mass by 57 Da. The precursor ion that would correspond to such an alkylation would have an m/z of 748.35 (2þ) plus 28.5 (CAM, the same 57, but doubly charged), or 776.85 (2þ). A closer inspection of the MS survey spectrum indeed identified a peak with m/z of 776.88 (2þ), suggesting that the alkylated above-mentioned peptide may indeed have an additional alkylation (Fig. 6C) produced a series of b and y product ions very similar to the previous peptide (748.35) as shown by identical y9, y8, y7, and y6 ion series, suggesting that peptide CFQGNQFLR has only the cysteine modified to CAM (Fig. 6D) .
Upon inspection of the b and a ions, we observed that the high intensity a2-b2 ion pair separated by 28 Da in the low mass region has shifted in mass in the MS/MS spectrum of the peptide with m/z of 776.88 (2þ). The mass difference between the a2 ion with m/z of 299.15 ( Fig. 6B; a2 of precursor 748.35 ) and the a2 ion with m/z of 356.18 ( Fig. 6D; a2 of precursor 776.88) is 57.03 and the same difference is also found between the b2 ions. Also, the b1 ion of the peptide with m/z of 776.88 (2þ) has shifted by 56.93 (193.11-136.08 ) from that of the peptide with m/z of 748.35 (2þ), indicating an IAA addition to the N-terminal tyrosine of the peptide. Taken together, we identified a cysteine-containing peptide that is alkylated to CAM (a predicted alkylation), but also modified by IAA at the N-terminal amino acid (an unpredicted modification).
Challenges
Although MS is an excellent method to identify and even quantify PTMs in complex samples, there are still some issues with the technique that need to be addressed. Most of these problems are inherent to the technique itself. For instance, there are many peptides that are not identifiable because they co-elute or their m/z overlaps. Another issue is the broad dynamic range encountered in complex samples with PTMs in usually very low-abundance. [134] [135] [136] However, this could be addressed by the development of mass spectrometers with greater resolution and sensitivity (high-energy collisional dissociation HCD, Q Exactive MS, High Definition Ion Mobility SYNAPT MS, LTQ Ion Trap Orbitrap MS), a trend that is observable more recently. [137] Another helpful tool in reducing sample complexity is the enrichment step which is currently standard. However, with the exception of phosphoproteomics, enrichment factors are usually well below 100 % for other PTMs-based proteomic experiments. Another general disadvantage is the extreme reliance on trypsin in MS-based proteomics experiments. For instance, PTMs could structurally hinder trypsin access to its cleavage sites or the modification could lie in a region with excessive or scarce tryptic cleavage sites. These issues would significantly decrease the sequence coverage of modified proteins. One way to circumvent this is to use an additional enzyme besides trypsin to increase coverage (e.g. trypsin-AspN double digestion, as shown in Figs. 1-2) . Similarly, IAA, which is often used in tryptic digests as a cysteine-alkylating reagent after reduction of disulfide bonds, has been shown to inhibit DUB activity. IAA can react with the a-amino group of lysine to yield 2-acetamidoacetamide that has the same molecular mass as di-Gly. To avoid this situation, it is advisable to use chloroacetamide, N-ethylmaleimide, or vinylpyridine instead of IAA as alkylating and DUB inhibiting reagents. [138, 139] Another point that needs to be addressed in the analysis of PTMs by MS is the single focus on one modification at a time ignoring that many distinct modifications can be present simultaneously on a protein. This deficit is probably due to the lack of available techniques able to enrich two or more distinct modified proteins or peptide concomitantly. Multi-modified peptides are very less represented in the proteome and are more labile than mono-modified moieties. In addition, detection of manifold modified peptides is hindered by their multiple neutral losses and little backbone fragmentation upon CID.
Conclusions
Protein PTMs play an important role in biology. MS and proteomics are ideal tools for the investigation of PTMs, given that most modifications of proteins result in mass shifts that can be identified by MS. Understanding of PTMs analysis by proteomics require an understanding of the chemistry behind these modifications. This could also help in the effort of discovering existing but yet non-identified protein modifications. In addition, site localisation of the PTMs is possible by performing MS/ MS sequencing, something that would be difficult to achieve with chemical or biochemical methods. Discovery, nonhypothesis analysis as well as targeted techniques (e.g. selected reaction monitoring or multiple reaction monitoring) can be applied for proteome-wide PTMs analysis with the latter method serving as a validation step. One puzzling observation is the fact that experimental data from proteomics experiment are always matched against a database of known proteins. Therefore, unassigned or unmatched experimental data are automatically considered 'junk,' which might not be necessarily the case. These unmatched data could be verified manually for relevant information even though this will be very time consuming. Besides, the continued development of MS with higher resolution, mass accuracy, sensitivity and efficient data analysis software will help expand the discovery of common and de novo protein modifications.
